ACXP241115C1000
- 0.00
- 0.000.00%
Acurx Pharmaceuticals Newsroom
Maxim Group Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $10
Promising Prospects for Acurx Pharmaceuticals: Buy Rating Backed by Ibezapolstat's Efficacy and Strategic Positioning
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
Maxim Group Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $10
Maxim Group Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $10
Buy Rating Affirmed for Acurx Pharmaceuticals Amid Positive Phase 2b Results and Strategic Pathway to Phase 3 Trials
Acurx Pharmaceuticals Analyst Ratings
Ibezapolstat's Strategic Advancements and Market Potential Bolster Buy Rating for Acurx Pharmaceuticals
Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid Financials
H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating
Acurx Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $14 Price Target
Buy Rating for Acurx Pharmaceuticals Amid Promising Phase 2 Results and Positive Regulatory Momentum
Analysts' Top Healthcare Picks: Acurx Pharmaceuticals (ACXP), Champions Oncology (CSBR)
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Lisata Therapeutics (LSTA) and Acurx Pharmaceuticals (ACXP)
HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Raises Price Target to $14
Acurx Pharmaceuticals Analyst Ratings
Promising Future for Acurx Pharmaceuticals: A Buy Rating Backed by Strong Financials, Successful Clinical Trials, and Strategic Market Positioning